Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Santaris Pharma
Santaris Pharma Releases Positive Data on LNA-based Survivin Inhibitor
November 25th, 2008
Santaris Pharma announced that SPC3042, a RNA-based antisense oligonucleotide developed using the company's proprietary Locked Nucleic Acid (LNA) technology, potently blocks survivin, a key survival protein in cancer cells, in both in vitro and in vivo models of prostate cancer. Importantly, SPC3042 works synergistically with the anticancer drug paclitaxel (Taxol(R)) in both model systems. The data on SPC3042 was published in the September 2008 issue of the journal Molecular Cancer Therapeutics. "This publication marks a milestone in our efforts to develop LNA-based RNA antagonists," said Santaris Pharma's CEO Soren Tulstrup. "SPC3042 is one of the most advanced...
Source: Cancer Weekly (2008-11-25)
|
